

# Galectin-3 as Biomarker

Subjects: Biology

Contributor: Akira Hara


Galectin-3, predominantly located in the cytoplasm and expressed on the cell surface, is a  $\beta$ -galactoside-binding lectin which is important in numerous biological activities in various organs, including cell proliferation, apoptotic regulation, inflammation, fibrosis, and host defense. Galectin-3 is often secreted into biological fluids, like serum and urine, thus used as a biomarker. It is also released from injured cells and inflammatory cells under various pathological conditions. Galectin-3 plays an important role as a diagnostic or prognostic biomarker for certain types of heart disease, kidney disease, viral infection, autoimmune disease, neurodegenerative disorders, and tumor formation. In particular, galectin-3 is extremely useful for detecting many of these diseases in their early stages.

Keywords: galectin-3 ; biomarker ; diagnostic ; prognostic ; early stage ; tumor ; animal model

## 1. Introduction

Galectins are a family of widely expressed  $\beta$ -galactoside-binding lectins in modulating “cell-to-cell” and “cell-to-matrix” interactions in all organisms [1][2][3]. Mammalian galectins have either one or two highly conserved carbohydrate recognition domains (CRDs), recognizing  $\beta$ -galactoside residues, to form complexes that crosslink glycosylated ligands [4][5][6].

Galectins have been classified into three subgroups according to their CRD number and function (Figure 1): (1) Proto-type galectins (galectin-1, -2, -5, -7, -10, -11, -13, -14, and -15), containing a single CRD that form non-covalent homodimers, (2) tandem-repeat galectins (galectin-4, -6, -8, -9, and -12), carrying two CRD motifs connected by a peptide linker, and (3) chimera-type galectin (galectin-3), which are characterized by having a single CRD and an amino-terminal polypeptide tail region [2][5][6]. All members of galectin family were numbered consecutively by order of discovery (Figure 1). Galectins are ubiquitously present in vertebrates, invertebrates, and also protists [1].



**Figure 1.** Schematic diagram of galectin family members. Galectin members are divided into three types based on the organization of galectin carbohydrate recognition domain (CRD).


Galectins play important roles in cell-to-cell and cell-to-matrix interactions by binding to endogenous glycans. Galectin signaling can regulate cellular functions at the cell surface. Biological functions of galectins, which are not yet fully

understood, include roles in development, tissue regeneration, regulation of immune cell activities, and other important cellular functions [1][2].

Galectins are important regulators of inflammatory responses and immune system. In fact, galectins are expressed in many inflammatory cells, such as macrophages [7]. Depending on the inflammatory environment, galectins promote pro-inflammatory or anti-inflammatory responses [2][5][6]. Recently, the galectin-mediated specific molecular recognition of glycans on the cell surface have revealed their roles as innate immune functions against potential pathogens and parasites. As a part of the innate immune system for microbial recognition/effector functions, galectins bind to exogenously exposed glycans on the surface of viruses, bacteria, fungi, and parasites [3].

## 2. Clinical Significance and Applications of Galectine-3 (Gal-3)

Gal-3, approximately 30 kDa chimera-type galectin, is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. Gal-3, to an equal or greater extent than other galectins, plays an important role in cell-to-cell or cell-to-matrix interactions, cell growth and differentiation, macrophage activation, antimicrobial activity, angiogenesis, and apoptosis [8]. Extracellular and intracellular activities of Gal-3 are shown in [Figure 2](#), with references detailed in the caption.



**Figure 2.** Schematic structure of galectin-3 and the intracellular and extracellular functions.

Recently, Gal-3 has been indicated to be involved in the following broad pathological processes: Inflammation [9], fibrosis, cell-to-cell [10][11] or cell-to-matrix [12] contacts, cell proliferation [13][14], and protection from apoptosis [15][16]. Furthermore, many studies have revealed that Gal-3 expression is detected in many disease conditions, such as heart disease [17][18][19][20][21][22][23], kidney disease [24][25][26][27], diabetes mellitus [24][25][28], viral infection [29][30][31][32], autoimmune disease [33][34][35][36], neurodegenerative disorders [37][38][39][40][41][42], and tumor formation [43][44][45][46][47][48][49][50][51][52].

Since Gal-3 is readily secreted to the cell surface and into biological fluids (e.g., serum and urine), from injured cells and inflammatory cells, Gal-3 may be used as a sensitive diagnostic or prognostic biomarker for various pathological conditions [44][52][53][54]. Furthermore, Gal-3 may also be useful for detecting very early stage of some diseases. Gal-3 has already been used as a novel biomarker in the early detection of myocardial dysfunction and heart failure [55]. Gal-3 has been validated as a biomarker of fibrotic degeneration in acute myocarditis following cardiac viral infection. In an animal model of heart failure, serum Gal-3 levels was shown to be used as a diagnostic biomarker for early detection of cardiac degeneration in acute myocarditis [31] and acute myocardial infarction [56]. Furthermore, Gal-3 is also a good specific marker for indicating the early stage of glioma tumorigenesis [43].

Serum levels of Gal-3 are usually determined by enzyme-linked immunosorbent assay (ELISA) using commercially available materials [57][58]. The localization or time-course of Gal-3 expression in various organs are examined immunohistochemically using commercially available anti-Gal-3 antibodies [31]. Gal-3 levels may be changed by different clinical factors in patients, depending on the underlying pathological conditions. Some previous studies indicated contradicting results on the association between Gal-3 levels and the prediction of clinical outcomes [59][60][61]. These studies, however, might be limited by the insufficient size of the clinical sample. In this review, we discuss and summarize recent developments of the biomarker characteristics and long-term outcome prediction of Gal-3 in patients with various

types of diseases (Table 1) as well as associated animal models (Table 2). Furthermore, we provide an overview of Gal-3 as a next-generation biomarker for detecting early stage of various diseases.

**Table 1.** Galectin-3 expression in various diseases and potential use as clinical biomarkers.

	Diseases	Usage of Biomarker	Potential Use as Biomarkers	Refs.
Heart disease	acute heart failure	plasma level	combination with natriuretic peptide	[62]
	acute heart failure	plasma level	promising prognostic marker	[63]
	chronic heart failure	plasma level	useful in HF patients with preserved LVEF	[64]
	chronic heart failure	myocardial and plasma level	not associated with histology	[65]
	acute myocardial infarction	serum level	no definite relationship with ventricular remodeling	[66]
Nervous system diseases	myelin degeneration	tissues	activation of the phagocytosis of degenerated myelin	[42]
	intracerebral hemorrhage	plasma level	prognostic predictor	[67]
	subarachnoid hemorrhage	plasma level	prognostic predictor	[68]
	global brain ischemia	cerebrospinal fluid	prognostic marker and inflammatory mediator	[69]
Renal disease	CKD	plasma level	associated with progression of CKD	[25]
	SLE nephritis	serum and biopsy specimens	associated with SLE patients, particularly in SLE nephritis	[70]
Liver disease	liver fibrosis	serum Gal-3 related binding protein	assessing liver fibrosis	[71]
Connective tissue diseases	rheumatoid arthritis	serum level	increased in early rheumatoid arthritis	[72]
	SLE	serum anti-Gal-3 antibody	a key role in SLE skin lesions	[73]
	systemic sclerosis	serum level	predictor of mortality	[74]
Neoplasms	colorectal cancer	serum and tissues	related to tumor progression	[52]
	breast cancer	human cell lines	important factor for treatment	[75]
	non-small cell lung cancer	tumor expression	promotion of invasion and metastasis	[76]
	lung and prostate cancers	tumor expression	therapeutic target of tumor immunity	[77]
	cervical cancer	tumor expression	targets of multifunctional cancer treatment	[78]
	thyroid cancer	tumor expression	diagnostic marker	[79]

**Table 2.** Galectin-3 expression and findings as biomarkers in animal models.

	Animal Models	Experimental Methods	Experimental Findings	Refs.
Heart disease	chronic heart failure	intrapericardial injection of recombinant Gal-3	myocardial fibrosis and its pharmacological inhibition	[80]
	chronic heart failure	intrapericardial infusion of low-dose Gal-3	increased Gal-3 in hypertrophied hearts	[81]
	chronic heart failure	banding of the pulmonary artery	increase of Gal-3 in ventricles	[82]
	acute heart failure	viral myocarditis	time-course analysis of cardiac and serum Gal-3	[31]

	Animal Models	Experimental Methods	Experimental Findings	Refs.
Nervous system diseases	multiple sclerosis	EAE in Gal-3-deficient mice	reduction in severity of EAE	[83]
	multiple sclerosis	spinal cord in EAE	Gal-3 observed at early stage before symptoms	[84]
	Huntington's disease	mouse model of Huntington's disease	plasma and brain Gal3 levels correlated with disease severity	[40]
	brain ischemia	time course analysis of Gal-3 in hippocampus	usefulness of early stage of Gal-3 for ischemic brain	[39]
	brain ischemia	temperature-dependent enhancement of Gal-3	hypothermic prevention of Gal-3	[30]
	cerebral infarction	cerebral artery occlusion	up-regulated Gal-3 in late stage of permanent ischemia	[85]
Renal disease	renal ischemia	Gal-3 deficient mice	less acute renal tubular necrosis	[86]
	renal fibrosis	unilateral ureteral obstruction	renal fibroblast activation by macrophage-secreted Gal-3	[87]
	renal ischemia	unilateral ureteral obstruction	Gal-3 protect renal tubules	[88]
	lipid-induced renal injury	Gal-3 deficient mice	more marked in Gal-3 deficient mice	[89]
Liver disease	NAFLD/NASH	Gal-3 deficient mice	attenuated inflammation and fibrosis	[90]
Connective tissue diseases	SLE	anti-Gal-3 antibody injected into skin	induction of lupus-like histologic changes	[73]
	glioma	analysis of preneoplastic lesions	expressed in preneoplastic lesions	[43]
Neoplasms	ovarian cancer	ovarian cancer xenografted mice.	galectin-3 maintains ovarian cancer stem cells	[91]
	oral cancer	Gal-3 deficient mice	no significant difference	[92]

## 3. Gal-3 and Heart Disease

### 3.1. Clinical Use of Gal-3 as a Possible Biomarker in Heart Disease

Recently, many reports have indicated that Gal-3 is a novel biomarker of heart disease and a prognostic indicator of patients with heart failure.

Clinical studies suggest that serum and myocardial Gal-3 levels in patients with heart failure reflects cardiac inflammatory condition and can be considered as a useful biomarker for both cardiac inflammation and fibrosis, depending on the pathophysiological mechanisms of heart failure [93]. In the general population, a high concentration of plasma Gal-3 correlates with clinical outcomes of heart failure [94][95]. The increased serum levels of Gal-3 are associated with adverse clinical events in both patients with acute [62][63] and chronic [64][65] heart failure with preserved or reduced ejection fraction.

### 3.2. Established Biomarkers in Heart Disease

Some practical guidelines have indicated the utility of established or recommended biomarkers in diagnosis and risk management of heart failure. In fact, American College of Cardiology Foundation (ACC)/American Heart Association (AHA), Heart Failure Society of America (HFSA), and European Society of Cardiology (ESC) have established the natriuretic peptides (NPs), circulating hormones of cardiac origin that play an important role in the regulation of intravascular blood volume and vascular tone, as useful diagnostic biomarkers in the patients suspected of heart failure [96][97][98][99]. However, the utilities of novel biomarkers other than NPs are less established in clinical practice. The recommendations on the clinical assessment and analytical perspectives of novel biomarkers in diagnosis and management of heart failure were prepared by the National Academy of Clinical Biochemistry (NACB) [100]. In these criteria, novel biomarkers need to be able to recognize fundamental causes of heart failure, assess its severity, and foresee the risk of the disease progression. The ACC/AHA guidelines recommended the use of Gal-3 as a biomarker for assessment of myocardial fibrosis in heart failure, however, the ESC has not recommended the clinical use of Gal-3 [101].

### 3.3. Gal-3 as a Biomarker of Fibrosis

Myocardial fibrosis is tightly implicated in the pathophysiological mechanisms for ventricular remodeling of heart failure. As a potential key factor in pathophysiology of heart failure, US Food and Drug Administration has approved Gal-3 as soluble biomarkers for myocardial fibrosis to detect ventricular remodeling [96]. Thus, the serum levels of Gal-3 are associated with ventricular remodeling and cardiac function. However, whether and how Gal-3 plays a pathophysiological role in cardiac remodeling remains unclear, especially in clinical settings. In fact, the serum levels of Gal-3 was not related to left ventricular remodeling defined by cardiac MRI in patients with acute myocardial infarction and left ventricular dysfunction, although certain biomarkers involved in extracellular matrix turnover, such as matrix metalloproteinase-3 and monocyte chemoattractant protein-1 at baseline (mean 46 h), were highly associated [66]. In addition, Srivatsan et al. conducted a study that found that Gal-3 could not predict mortality, while other biomarkers could be used as a predictor of mortality [102].

### 3.4. Usefulness of Gal-3 in Animal Models

As mentioned above, the roles of Gal-3 in heart failure and cardiovascular disease are still controversial clinically, however, many animal models clearly demonstrate the possibility of Gal-3 as a novel biomarker of heart disease. Overexpression of myocardial Gal-3 during early pre-symptomatic stages of heart failure has been well documented in several studies using animal models. Intrapericardial injection of recombinant Gal-3 in healthy rats significantly increased the degree of myocardial fibrosis with ventricular remodeling, and the induction of heart failure [80][81]. And Gal-3 was indicated to colocalize with activated myocardial macrophages [80]. On the other hand, cardiac remodeling and dysfunction induced by Gal-3 was prevented by a pharmacological inhibitor of Gal-3, N-acetyl-seryl-aspartyl-lysyl-proline [80]. In a rat model of heart failure, increased Gal-3 was detected at hypertrophied hearts, prior to the development of heart failure [81]. These findings imply that Gal-3, at the early stages of inflammatory responses, may be a potential therapeutic target in the treatment of heart failure. A rat model of right ventricular heart failure, created by banding of the pulmonary artery, demonstrated that Gal-3 was significantly increased in both right and left ventricles and that protein kinase C promoted cardiac fibrosis and heart failure by modulating Gal-3 expression [82]. In order to clarify the important role of myocardial Gal-3 expression during the early stage of heart failure, the time-course analysis of cardiac and serum Gal-3 in viral myocarditis, which was induced at 12, 24, 48, 96 h, 7 and 10 days after specific virus-inoculation, was performed using an animal model [31]. Gal-3 was indicated as a useful histological biomarker of cardiac fibrosis in acute myocarditis following viral infection and serum Gal-3 levels might be an early diagnostic method for detecting cardiac fibrotic degeneration in acute myocarditis [31].

However, the clinical data has not shown that circulating Gal-3 levels reflect myocardial Gal-3 levels or myocardial fibrosis, although circulating Gal-3 has been demonstrated as a potential predictor for clinical outcome in several cohort studies, as mentioned earlier [94][95]. In clinical settings, since various stages and degrees of myocardial inflammation and fibrosis may be present in a patient with heart disease, serum Gal-3 levels may reflect a sum of different pathophysiological conditions [93]. Thus, it may be that the circulating Gal-3 levels in a patient with various stages of heart disease will not adequately reflect myocardial inflammation and fibrosis.

### 3.5. Clinical Use of Gal-3 as a Next-Generation Biomarker in the Future

Endomyocardial biopsy is widely used as a diagnostic tool for patients with heart diseases, such as myocarditis and other cardiomyopathies, which are often difficult to diagnose by conventional radiological imaging methods [103]. The histologic examination of endomyocardial biopsy is still the gold standard for final diagnosis, such as for myocarditis and other cardiomyopathies like cardiac fibrosis, despite the continuous advancements in diagnostic and therapeutic approaches [104][105][106].

Unlike uniform materials from experimental animals, there are many variables in human biopsy materials by its nature. Human biopsies are usually obtained under different conditions, e.g., variable time periods between biopsy and processing, as well as variation in disease onset or severity. In contrast, the serum levels of Gal-3 reflect myocardial Gal-3 expression or cardiac fibrosis by using a sophisticated animal model for time-course histological examination [31]. It is possible that the difference between experimental data and clinical findings is due to a wide variability in clinical settings with differences in sample collection and disease stages. Since experimental animal data clearly indicate that serum Gal-3 might be an early diagnostic biomarker for cardiac degeneration or fibrosis in acute myocarditis [31], further studies are thus needed to investigate whether such findings are also applicable to cardiac degeneration or fibrosis in humans. Gal-3 can be used as a predictive biomarker for the early stage or new-onset of heart failure, especially if it is only the first single pathological factor. In addition, Gal-3 can also be used as an additional indicator for detecting worse prognosis, mortality, and readmission.

## References

1. Liu, F.T.; Patterson, R.J.; Wang, J.L. Intracellular functions of galectins. *Biochim. Biophys. Acta Gen. Subj.* 2002, 1572, 263–273.
2. Yang, R.Y.; Rabinovich, G.A.; Liu, F.T. Galectins: Structure, function and therapeutic potential. *Expert Rev. Mol. Med.* 2008, 10, e17.
3. Chen, H.Y.; Weng, I.C.; Hong, M.H.; Liu, F.T. Galectins as bacterial sensors in the host innate response. *Curr. Opin. Microbiol.* 2014, 17, 75–81.
4. Barondes, S.H.; Castronovo, V.; Cooper, D.N.W.; Cummings, R.D.; Drickamer, K.; Felzi, T.; Gitt, M.A.; Hirabayashi, J.; Hughes, C.; Kasai, K.I.; et al. Galectins: A family of animal  $\beta$ -galactoside-binding lectins. *Cell* 1994, 76, 597–598.
5. Nabi, I.R.; Shankar, J.; Dennis, J.W. The galectin lattice at a glance. *J. Cell Sci.* 2015, 128, 2213–2219.
6. Johannes, L.; Jacob, R.; Leffler, H. Galectins at a glance. *J. Cell Sci.* 2018, 131, jcs208884.
7. Paclik, D.; Werner, L.; Guckelberger, O.; Wiedenmann, B.; Sturm, A. Galectins distinctively regulate central monocyte and macrophage function. *Cell. Immunol.* 2011, 271, 97–103.
8. Dumic, J.; Dabelic, S.; Flögel, M. Galectin-3: An open-ended story. *Biochim. Biophys. Acta Gen. Subj.* 2006, 1760, 616–635.
9. Stitt, A.W.; He, C.; Vlassara, H. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. *Biochem. Biophys. Res. Commun.* 1999, 256, 549–556.
10. Inohara, H.; Raz, A. Functional Evidence that Cell Surface Galectin-3 Mediates Homotypic Cell Adhesion. *Cancer Res.* 1995, 55, 3267–3271.
11. Ochieng, J.; Leite-Browning, M.L.; Warfield, P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. *Biochem. Biophys. Res. Commun.* 1998, 246, 788–791.
12. Vlassara, H.; Li, Y.M.; Imani, F.; Wojciechowicz, D.; Yang, Z.; Liu, F.T.; Cerami, A. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): A new member of the AGE-receptor complex. *Mol. Med.* 1995, 1, 634–646.
13. Dagher, S.F.; Wang, J.L.; Patterson, R.J. Identification of galectin-3 as a factor in pre-mRNA splicing. *Proc. Natl. Acad. Sci. USA* 1995, 92, 1213–1217.
14. Kim, H.R.C.; Lin, H.M.; Biliran, H.; Raz, A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. *Cancer Res.* 1999, 59, 4148–4154.
15. Yang, R.Y.; Hsu, D.K.; Liu, F.T. Expression of galectin-3 modulates T-cell growth and apoptosis. *Proc. Natl. Acad. Sci. USA* 1996, 93, 6737–6742.
16. Akahani, S.; Nangia-Makker, P.; Inohara, H.; Kim, H.R.C.; Raz, A. Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. *Cancer Res.* 1997, 57, 5272–5276.
17. Clementy, N.; Garcia, B.; André, C.; Bisson, A.; Benhenda, N.; Pierre, B.; Bernard, A.; Fauchier, L.; Piver, E.; Babuty, D. Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. *PLoS ONE* 2018, 13, e0201517.
18. Andre, C.; Piver, E.; Perault, R.; Bisson, A.; Pucheux, J.; Vermes, E.; Pierre, B.; Fauchier, L.; Babuty, D.; Clementy, N. Galectin-3 predicts response and outcomes after cardiac resynchronization therapy 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology. *J. Transl. Med.* 2018, 16, 299.
19. Zuern, C.S.; Floss, N.; Mueller, I.I.; Eick, C.; Duckheim, M.; Patzelt, J.; Gawaz, M.; May, A.E.; Mueller, K.A.L. Galectin-3 is associated with left ventricular reverse remodeling and outcome after percutaneous mitral valve repair. *Int. J. Cardiol.* 2018, 263, 104–110.
20. Asleh, R.; Enriquez-Sarano, M.; Jaffe, A.S.; Manemann, S.M.; Weston, S.A.; Jiang, R.; Roger, V.L. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study. *J. Am. Coll. Cardiol.* 2019, 73, 2286–2295.
21. Cui, Y.; Qi, X.; Huang, A.; Li, J.; Hou, W.; Liu, K. Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction. *Med. Sci. Monit.* 2018, 24, 5139–5146.
22. Dupuy, A.M.; Kuster, N.; Curinier, C.; Huet, F.; Plawecki, M.; Solecki, K.; Roubille, F.; Cristol, J.P. Exploring collagen remodeling and regulation as prognosis biomarkers in stable heart failure. *Clin. Chim. Acta* 2019, 490, 167–171.
23. Ghorbani, A.; Bhamhani, V.; Christenson, R.H.; Meijers, W.C.; de Boer, R.A.; Levy, D.; Larson, M.G.; Ho, J.E. Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes. *J. Am. Coll. Cardiol.* 2018, 72, 3246–3254.

24. Tan, K.C.B.; Cheung, C.-L.; Lee, A.C.H.; Lam, J.K.Y.; Wong, Y.; Shiu, S.W.M. Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus. *Diabetologia* 2018, 61, 1212–1219.
25. Alam, M.L.; Katz, R.; Bellovich, K.A.; Bhat, Z.Y.; Brosius, F.C.; de Boer, I.H.; Gadegbeku, C.A.; Gipson, D.S.; Hawkins, J.J.; Himmelfarb, J.; et al. Soluble ST2 and Galectin-3 and Progression of CKD. *Kidney Int. Rep.* 2019, 4, 103–111.
26. Savoj, J.; Becerra, B.; Kim, J.K.; Fusaro, M.; Gallieni, M.; Lombardo, D.; Lau, W.L. Utility of Cardiac Biomarkers in the Setting of Kidney Disease. *Nephron* 2019, 141, 227–235.
27. Chen, S.C.; Kuo, P.L. The role of galectin-3 in the kidneys. *Int. J. Mol. Sci.* 2016, 17, 565.
28. Gopal, D.M.; Ayalon, N.; Wang, Y.C.; Siwik, D.; Sverdlow, A.; Donohue, C.; Perez, A.; Downing, J.; Apovian, C.; Silva, V.; et al. Galectin-3 is associated with stage B metabolic heart disease and pulmonary hypertension in young obese patients. *J. Am. Heart Assoc.* 2019, 8, e011100.
29. Sato, S.; Ouellet, M.; St-Pierre, C.; Tremblay, M.J. Glycans, galectins, and HIV-1 infection. *Ann. N. Y. Acad. Sci.* 2012, 1253, 133–148.
30. Nielsen, C.T.; Østergaard, O.; Rasmussen, N.S.; Jacobsen, S.; Heegaard, N.H.H. A review of studies of the proteomes of circulating microparticles: Key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosus. *Clin. Proteom.* 2017, 14, 11.
31. Noguchi, K.; Tomita, H.; Kanayama, T.; Niwa, A.; Hatano, Y.; Hoshi, M.; Sugie, S.; Okada, H.; Niwa, M.; Hara, A. Time-course analysis of cardiac and serum galectin-3 in viral myocarditis after an encephalomyocarditis virus inoculation. *PLoS ONE* 2019, 14, e0210971.
32. Kobayashi, K.; Niwa, M.; Hoshi, M.; Saito, K.; Hisamatsu, K.; Hatano, Y.; Tomita, H.; Miyazaki, T.; Hara, A. Early microlesion of viral encephalitis confirmed by galectin-3 expression after a virus inoculation. *Neurosci. Lett.* 2015, 592, 107–112.
33. De Oliveira, F.L.; Gatto, M.; Bassi, N.; Luisetto, R.; Ghirardello, A.; Punzi, L.; Doria, A. Galectin-3 in autoimmunity and autoimmune diseases. *Exp. Biol. Med.* 2015, 240, 1019–1028.
34. Dhirapong, A.; Lleo, A.; Leung, P.; Gershwin, M.E.; Liu, F.T. The immunological potential of galectin-1 and -3. *Autoimmun. Rev.* 2009, 8, 360–363.
35. Shin, T. The pleiotropic effects of galectin-3 in neuroinflammation: A review. *Acta Histochem.* 2013, 115, 407–411.
36. Saccon, F.; Gatto, M.; Ghirardello, A.; Iaccarino, L.; Punzi, L.; Doria, A. Role of galectin-3 in autoimmune and non-autoimmune nephropathies. *Autoimmun. Rev.* 2017, 16, 34–47.
37. Satoh, K.; Niwa, M.; Binh, N.H.; Nakashima, M.; Kobayashi, K.; Takamatsu, M.; Hara, A. Increase of galectin-3 expression in microglia by hyperthermia in delayed neuronal death of hippocampal CA1 following transient forebrain ischemia. *Neurosci. Lett.* 2011, 504, 199–203.
38. Hisamatsu, K.; Niwa, M.; Kobayashi, K.; Miyazaki, T.; Hirata, A.; Hatano, Y.; Tomita, H.; Hara, A. Galectin-3 expression in hippocampal CA2 following transient forebrain ischemia and its inhibition by hypothermia or antiapoptotic agents. *Neuroreport* 2016, 27, 311–317.
39. Satoh, K.; Niwa, M.; Goda, W.; Binh, N.H.; Nakashima, M.; Takamatsu, M.; Hara, A. Galectin-3 expression in delayed neuronal death of hippocampal CA1 following transient forebrain ischemia, and its inhibition by hypothermia. *Brain Res.* 2011, 1382, 266–274.
40. Siew, J.J.; Chen, H.M.; Chen, H.Y.; Chen, H.L.; Chen, C.M.; Soong, B.W.; Wu, Y.R.; Chang, C.P.; Chan, Y.C.; Lin, C.H.; et al. Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington's disease. *Nat. Commun.* 2019, 10, 3473.
41. Ashraf, G.M.; Baeesa, S.S. Investigation of Gal-3 Expression Pattern in Serum and Cerebrospinal Fluid of Patients Suffering From Neurodegenerative Disorders. *Front. Neurosci.* 2018, 12, 430.
42. Rotshenker, S. The role of Galectin-3/MAC-2 in the activation of the innate-immune function of phagocytosis in microglia in injury and disease. *J. Mol. Neurosci.* 2009, 39, 99–103.
43. Binh, N.H.; Satoh, K.; Kobayashi, K.; Takamatsu, M.; Hatano, Y.; Hirata, A.; Tomita, H.; Kuno, T.; Hara, A. Galectin-3 in preneoplastic lesions of glioma. *J. Neurooncol.* 2013, 111, 123–132.
44. Song, L.; Tang, J.W.; Owusu, L.; Sun, M.Z.; Wu, J.; Zhang, J. Galectin-3 in cancer. *Clin. Chim. Acta* 2014, 431, 185–191.
45. Fortuna-Costa, A.; Gomes, A.M.; Kozłowski, E.O.; Stelling, M.P.; Pavão, M.S.G. Extracellular galectin-3 in tumor progression and metastasis. *Front. Oncol.* 2014, 4, 138.
46. Funasaka, T.; Raz, A.; Nangia-Makker, P. Galectin-3 in angiogenesis and metastasis. *Glycobiology* 2014, 24, 886–891.

47. Xin, M.; Dong, X.W.; Guo, X.L. Role of the interaction between galectin-3 and cell adhesion molecules in cancer metastasis. *Biomed. Pharmacother.* 2015, 69, 179–185.
48. Ruvolo, P.P. Galectin 3 as a guardian of the tumor microenvironment. *Biochim. Biophys. Acta Mol. Cell Res.* 2016, 1863, 427–437.
49. Zeinali, M.; Adelink, A.; Papian, S.; Khorramdelazad, H.; Abedinzadeh, M. Role of galectin-3 in the pathogenesis of bladder transitional cell carcinoma. *Hum. Immunol.* 2015, 76, 770–774.
50. Wang, L.; Guo, X.L. Molecular regulation of galectin-expression and therapeutic implication in cancer progression. *Bio med. Pharmacother.* 2016, 78, 165–171.
51. Nangia-Makker, P.; Hogan, V.; Raz, A. Galectin-3 and cancer stemness. *Glycobiology* 2018, 28, 172–181.
52. Wang, C.; Zhou, X.; Ma, L.; Zhuang, Y.; Wei, Y.; Zhang, L.; Jin, S.; Liang, W.; Shen, X.; Li, C.; et al. Galectin-3 may serve as a marker for poor prognosis in colorectal cancer: A meta-analysis. *Pathol. Res. Pract.* 2019, 215, 152612.
53. Dong, R.; Zhang, M.; Hu, Q.; Zheng, S.; Soh, A.; Zheng, Y.; Yuan, H. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). *Int. J. Mol. Med.* 2018, 41, 599–614.
54. Dimitroff, C.J. Galectin-binding O-glycosylations as regulators of malignancy. *Cancer Res.* 2015, 75, 3195–3202.
55. De Couto, G.; Ouzounian, M.; Liu, P.P. Early detection of myocardial dysfunction and heart failure. *Nat. Rev. Cardiol.* 2010, 7, 334–344.
56. Hashmi, S.; Al-Salam, S. Galectin-3 is expressed in the myocardium very early post-myocardial infarction. *Cardiovasc. Pathol.* 2015, 24, 213–223.
57. Van Der Velde, A.R.; Meijers, W.C.; Ho, J.E.; Brouwers, F.P.; Rienstra, M.; Bakker, S.J.L.; Muller Kobold, A.C.; Van Veldhuisen, D.J.; Van Gilst, W.H.; Van Der Harst, P.; et al. Serial galectin-3 and future cardiovascular disease in the general population. *Heart* 2016, 102, 1134–1141.
58. Tang, W.H.W.; Shrestha, K.; Shao, Z.; Borowski, A.G.; Troughton, R.W.; Thomas, J.D.; Klein, A.L. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. *Am. J. Cardiol.* 2011, 108, 385–390.
59. López, B.; González, A.; Querejeta, R.; Zubillaga, E.; Larman, M.; Díez, J. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. *Eur. J. Heart Fail.* 2015, 17, 385–392.
60. Erkilet, G.; Özpeker, C.; Böthig, D.; Kramer, F.; Röfe, D.; Bohms, B.; Morshuis, M.; Gummert, J.; Milting, H. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. *J. Heart Lung Transplant.* 2013, 32, 221–230.
61. Beiras-Fernandez, A.; Weis, F.; Rothkopf, J.; Kaczmarek, I.; Ledderose, C.; Dick, A.; Keller, T.; Beiras, A.; Kreth, S. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation. *Ann. Transplant.* 2013, 18, 643–650.
62. Van Kimmenade, R.R.; Januzzi, J.L.; Ellinor, P.T.; Sharma, U.C.; Bakker, J.A.; Low, A.F.; Martinez, A.; Crijns, H.J.; MacRae, C.A.; Menheere, P.P.; et al. Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure. *J. Am. Coll. Cardiol.* 2006, 48, 1217–1224.
63. Agnello, L.; Bivona, G.; Lo Sasso, B.; Scazzone, C.; Bazan, V.; Bellia, C.; Ciaccio, M. Galectin-3 in acute coronary syndrome. *Clin. Biochem.* 2017, 50, 797–803.
64. De Boer, R.A.; Lok, D.J.A.; Jaarsma, T.; Van Der Meer, P.; Voors, A.A.; Hillege, H.L.; Van Veldhuisen, D.J. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. *Ann. Med.* 2011, 43, 60–68.
65. Lopez-Andrés, N.; Rossignol, P.; Iraqi, W.; Fay, R.; Nuée, J.; Ghio, S.; Cleland, J.G.F.; Zannad, F.; Lacolley, P. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. *Eur. J. Heart Fail.* 2012, 14, 74–81.
66. Weir, R.A.P.; Petrie, C.J.; Murphy, C.A.; Clements, S.; Steedman, T.; Miller, A.M.; McInnes, I.B.; Squire, I.B.; Ng, L.L.; Dargie, H.J.; et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. *Circ. Heart Fail.* 2013, 6, 492–498.
67. Yan, X.J.; Yu, G.F.; Jie, Y.Q.; Fan, X.F.; Huang, Q.; Dai, W.M. Role of galectin-3 in plasma as a predictive biomarker of outcome after acute intracerebral hemorrhage. *J. Neurol. Sci.* 2016, 368, 121–127.
68. Liu, H.; Liu, Y.; Zhao, J.; Liu, H.; He, S. Prognostic value of plasma galectin-3 levels after aneurysmal subarachnoid hemorrhage. *Brain Behav.* 2016, 6, e00543.
69. Sävman, K.; Heyes, M.P.; Svedin, P.; Karlsson, A. Microglia/Macrophage-Derived Inflammatory Mediators Galectin-3 and Quinolinic Acid are Elevated in Cerebrospinal Fluid from Newborn Infants after Birth Asphyxia. *Transl. Stroke Res.* 2019, 2, 1–10.

70. Kang, E.H.; Moon, K.C.; Lee, E.Y.; Lee, Y.J.; Lee, E.B.; Ahn, C.; Song, Y.W. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. *Lupus* 2009, 18, 22–28.
71. Shirabe, K.; Bekki, Y.; Gantumur, D.; Araki, K.; Ishii, N.; Kuno, A.; Narimatsu, H.; Mizokami, M. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: More than a biomarker of liver fibrosis. *J. Gastroenterol.* 2018, 53, 819–826.
72. Issa, S.F.; Christensen, A.F.; Lindegaard, H.M.; Hetland, M.L.; Hørslev-Petersen, K.; Stengaard-Pedersen, K.; Ejbjerg, B.J.; Lottenburger, T.; Ellingsen, T.; Pedersen, J.K.; et al. Galectin-3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti-CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity. *Scand. J. Immunol.* 2017, 86, 471–478.
73. Shi, Z.R.; Tan, G.Z.; Meng, Z.; Yu, M.; Li, K.W.; Yin, J.; Wei, K.H.; Luo, Y.J.; Jia, S.Q.; Zhang, S.J.; et al. Association of anti-acidic ribosomal protein P0 and anti-galectin 3 antibodies with the development of skin lesions in systemic lupus erythematosus. *Arthritis Rheumatol.* 2015, 67, 193–203.
74. Faludi, R.; Nagy, G.; Tőkés-Füzesi, M.; Kovács, K.; Cziráj, L.; Komócsi, A. Galectin-3 is an independent predictor of survival in systemic sclerosis. *Int. J. Cardiol.* 2017, 233, 118–124.
75. Boutas, I.; Potiris, A.; Brenner, W.; Lebrecht, A.; Hasenburg, A.; Kalantaridou, S.; Schmidt, M. The expression of galectin-3 in breast cancer and its association with chemoresistance: A systematic review of the literature. *Arch. Gynecol. Obstet.* 2019, 300, 1113–1120.
76. Jiang, X.N.; Dang, Y.F.; Gong, F.L.; Guo, X.L. Role and regulation mechanism of Gal-3 in non-small cell lung cancer and its potential clinical therapeutic significance. *Chem. Biol. Interact.* 2019, 309, 108724.
77. Farhad, M.; Rolig, A.S.; Redmond, W.L. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. *Oncoimmunology* 2018, 7, e1434467.
78. Wang, L.; Zhao, Y.; Wang, Y.; Wu, X. The role of galectins in cervical cancer biology and progression. *Biomed. Res. Int.* 2018, 2018, 2175927.
79. Chiu, C.G.; Strugnell, S.S.; Griffith, O.L.; Jones, S.J.M.; Gown, A.M.; Walker, B.; Nabi, I.R.; Wiseman, S.M. Diagnostic utility of galectin-3 in thyroid cancer. *Am. J. Pathol.* 2010, 176, 2067–2081.
80. Liu, Y.H.; D'Ambrosio, M.; Liao, T.D.; Peng, H.; Rhaleb, N.E.; Sharma, U.; Andre, S.; Gabius, H.J.; Carretero, O.A. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. *Am. J. Physiol. Heart Circ. Physiol.* 2009, 296, 404–412.
81. Sharma, U.C.; Pokharel, S.; Van Brakel, T.J.; Van Berlo, J.H.; Cleutjens, J.P.M.; Schroen, B.; André, S.; Crijns, H.J.G.M.; Gabius, H.J.; Maessen, J.; et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. *Circulation* 2004, 110, 3121–3128.
82. Song, X.; Qian, X.; Shen, M.; Jiang, R.; Wagner, M.B.; Ding, G.; Chen, G.; Shen, B. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. *Biochim. Biophys. Acta Mol. Cell Res.* 2015, 1853, 513–521.
83. Jiang, H.-R.; Al Rasebi, Z.; Mensah-Brown, E.; Shahin, A.; Xu, D.; Goodyear, C.S.; Fukada, S.Y.; Liu, F.-T.; Liew, F.Y.; Lukic, M.L. Galectin-3 Deficiency Reduces the Severity of Experimental Autoimmune Encephalomyelitis. *J. Immunol.* 2009, 182, 1167–1173.
84. Kobayashi, S.; Hara, A.; Isagawa, T.; Manabe, I.; Takeda, K.; Maruyama, T. The nuclear I $\kappa$ B family protein I $\kappa$ BNS influences the susceptibility to experimental autoimmune encephalomyelitis in a murine model. *PLoS ONE* 2014, 9, e110838.
85. Yan, Y.P.; Lang, B.T.; Vemuganti, R.; Dempsey, R.J. Galectin-3 mediates post-ischemic tissue remodeling. *Brain Res.* 2009, 1288, 116–124.
86. Fernandes Bertocchi, A.P.; Campanhole, G.; Wang, P.H.M.; Gonçalves, G.M.; Damião, M.J.; Cenedeze, M.A.; Beraldo, F.C.; De Paula Antunes Teixeira, V.; Dos Reis, M.A.; Mazzali, M.; et al. A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. *Transpl. Int.* 2008, 21, 999–1007.
87. Henderson, N.C.; Mackinnon, A.C.; Farnworth, S.L.; Kipari, T.; Haslett, C.; Iredale, J.P.; Liu, F.T.; Hughes, J.; Sethi, T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. *Am. J. Pathol.* 2008, 172, 288–298.
88. Okamura, D.M.; Pasichnyk, K.; Lopez-Guisa, J.M.; Collins, S.; Hsu, D.K.; Liu, F.T.; Eddy, A.A. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. *Am. J. Physiol. Ren. Physiol.* 2011, 300, 245–253.

89. Iacobini, C.; Menini, S.; Ricci, C.; Scipioni, A.; Sansoni, V. Advanced lipoxidation end-products mediate lipid-induced glomerular injury: Role of receptor-mediated mechanisms. *J. Pathol.* 2009, 218, 360–369.
90. Pejnovic, N.; Jetic, I.; Jovicic, N.; Arsenijevic, N.; Lukic, M.L. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis. *World J. Gastroenterol.* 2016, 22, 9706–9717.
91. Kang, H.G.; Kim, D.H.; Kim, S.J.; Cho, Y.; Jung, J.; Jang, W.; Chun, K.H. Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. *Oncotarget* 2016, 7, 68229–68241.
92. De Souza, M.V.R.; Servato, J.P.S.; Loyola, A.M.; Cardoso, S.V.; Chammas, R.; Liu, F.T.; Silva, M.J.B.; de Faria, P.R. Expression of APC protein during tongue malignant transformation in galectin-3-deficient mice challenged by the carcinogen 4-nitroquinoline-n-oxide. *Int. J. Clin. Exp. Pathol.* 2014, 7, 3255–3263.
93. Besler, C.; Lang, D.; Urban, D.; Rommel, K.P.; Von Roeder, M.; Fengler, K.; Blazek, S.; Kandolf, R.; Klingel, K.; Thiele, H.; et al. Plasma and cardiac galectin-3 in patients with heart failure reflects both inflammation and fibrosis: Implications for its use as a biomarker. *Circ. Heart Fail.* 2017, 10, e003804.
94. Ho, J.E.; Liu, C.; Lyass, A.; Courchesne, P.; Pencina, M.J.; Vasan, R.S.; Larson, M.G.; Levy, D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. *J. Am. Coll. Cardiol.* 2012, 60, 1249–1256.
95. De Boer, R.A.; van Veldhuisen, D.J.; Gansevoort, R.T.; Muller Kobold, A.C.; van Gilst, W.H.; Hillege, H.L.; Bakker, S.J. L.; van der Harst, P. The fibrosis marker galectin-3 and outcome in the general population. *J. Intern. Med.* 2012, 272, 55–64.
96. Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E.; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Horwich, T.; Januzzi, J.L.; et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. *J. Am. Coll. Cardiol.* 2013, 62, e147–e239.
97. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; González-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur. Heart J.* 2016, 37, 2129–2200.
98. Paul, S.; Lindenfeld, J.; Mann, D.L.; Albert, N.M.; Boehmer, J.P.; Collins, S.P.; Ezekowitz, J.A.; Givertz, M.M.; Katz, S.D.; Klapholz, M.; et al. Heart Failure Practice Guideline HFSA 2010 Comprehensive Heart Failure Practice Guideline. *J. Card. Fail.* 2010, 16, e1–e2.
99. Yancy, C.W.; Mariell Jessup, C.; Chair Biykem Bozkurt, V.; Butler, J.; Casey, D.E., Jr.; Colvin, M.M.; Drazner, M.H.; Filippatos, G.S.; Fonarow, G.C.; Givertz, M.M.; et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. *Circulation* 2017, 136, 137–161.
100. Tang, W.H.W.; Francis, G.S.; Morrow, D.A.; Newby, L.K.; Cannon, C.P.; Jesse, R.L.; Storrow, A.B.; Christenson, R.H.; Christenson, R.H.; Apple, F.S.; et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. *Clin. Biochem.* 2008, 41, 210–221.
101. Sarhene, M.; Wang, Y.; Wei, J.; Huang, Y.; Li, M.; Li, L.; Acheampong, E.; Zhengcan, Z.; Xiaoyan, Q.; Yunsheng, X.; et al. Biomarkers in heart failure: The past, current and future. *Heart Fail. Rev.* 2019, 24, 867–903.
102. Srivatsan, V.; George, M.; Shanmugam, E. Utility of galectin-3 as a prognostic biomarker in heart failure: Where do we stand? *Eur. J. Prev. Cardiol.* 2015, 22, 1096–1110.
103. Ishibashi-Ueda, H.; Matsuyama, T.A.; Ohta-Ogo, K.; Ikeda, Y. Significance and value of endomyocardial biopsy based on our own experience. *Circ. J.* 2017, 81, 417–426.
104. Basso, C.; Calabrese, F.; Angelini, A.; Carturan, E.; Thiene, G. Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease. *Heart Fail. Rev.* 2013, 18, 673–681.
105. Stone, J.R.; Basso, C.; Baandrup, U.T.; Bruneval, P.; Butany, J.; Gallagher, P.J.; Halushka, M.K.; Miller, D.V.; Padera, R.F.; Radio, S.J.; et al. Recommendations for processing cardiovascular surgical pathology specimens: A consensus statement from the Standards and Definitions Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology. *Cardiovasc. Pathol.* 2012, 21, 2–16.
106. Andréoletti, L.; Lévêque, N.; Boulagnon, C.; Brasselet, C.; Fornes, P. Viral causes of human myocarditis. *Arch. Cardiovasc. Dis.* 2009, 102, 559–568.